BIXT · Bioxytran, Inc.

Summary

Bioxytran, Inc. completed a private placement on March 18, 2026, issuing 21,071,667 shares of common stock at $0.055 per share for $1.2 million gross proceeds and warrants for 19,750,001 shares at $0.12 exercise price. The net proceeds will fund working capital and general corporate purposes, strengthening the balance sheet for development initiatives.

Key takeaways

• Issued 21,071,667 shares of common stock at $0.055 per share for $1.2 million gross proceeds on March 18, 2026
• Issued warrants to purchase 19,750,001 shares at $0.12 per share, exercisable immediately, expiring in five years
• Private placement to accredited investors under Section 4(a)(2) and Rule 506 of Regulation D
• Net proceeds for working capital and general corporate purposes, including development programs
• Press release issued March 20, 2026, announcing completion (Exhibit 99.1)
• CEO David Platt stated financing supports clinical initiatives and A-SUQAR launch this quarter